OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Gadgeel, S., Cho, B.C., Lu, S., Felip, E., Hayashi, H., Spira, A.I., Besse, B., Thomas, M., Owen, S., Kim, Y.J., Lee, S.-H., Mourão Dias, J., Lee, Y.-G., Zhao, Y., Fang, Y., Girard, N., Liu, Z., Sun, P., Oliveira, S.C. Sousa, Shen, H., Paz-Ares, L., Matsumoto, S., Tanaka, H., Ahmad, A.R., Andabekov, T., Sunpaweravong, P., Ozyilkan, O., Yang, J.C.-H., Gottfried, M., Hernandez, O., Kimmich, M., Cortinovis, D., Kaen, D.L., Montes, L.V. García, Popat, S., Newsom-Davis, T., Xie, J., Sun, T., Fennema, E., Daksh, M., Ennis, M., Sethi, S., Bauml, J.M., Nguyen, D.
Published in Journal of thoracic oncology (01.10.2024)
Published in Journal of thoracic oncology (01.10.2024)
Get full text
Journal Article